Amir Snapir

Amir Snapir has PhD from the University of Turku, Finland and MD from the University of Tel Aviv, Israel. He has extensive experience in global clinical development of novel therapeutics, combined with extensive international regulatory experience. Dr Snapir also has years of experience in business collaborations, alliances and product co-developments. His earlier positions include CMO of PCI Biotech, where he was responsible for the clinical development of drug-device combination product candidates, and leader of clinical pharmacogenomics and clinical development leader in Oncology at Orion Pharma.